

## **Production of Active Human Glucocerebrosidase in Seeds of *Arabidopsis thaliana* Complex-Glycan-Deficient (*cgl*) Plants**

**Xu He<sup>2</sup>, Jason D. Galpin<sup>2</sup>, Michael B. Tropak<sup>3</sup>, Don Mahuran<sup>3,4</sup>, Thomas Haselhorst<sup>5</sup>, Mark von Itzstein<sup>5</sup>, Daniel Kolarich<sup>6</sup>, Nicolle H. Packer<sup>6</sup>, Yansong Miao<sup>7</sup>, Liwen Jiang<sup>7</sup>, Gregory A. Grabowski<sup>8</sup>, Lorne A. Clarke<sup>9</sup>, and Allison R. Kermode<sup>1,2</sup>**

<sup>2</sup>Department of Biological Sciences, Simon Fraser University, 8888 University Dr., Burnaby, BC, Canada V5A 1S6;

<sup>3</sup>Research Institute, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada;

<sup>4</sup>Department of Laboratory Medicine and Pathology, University of Toronto, Banting Institute, 100 College Street, Toronto, Ontario M5G 1L5, Canada;

<sup>5</sup>Institute for Glycomics, Griffith University, Gold Coast Campus, Queensland 4222, Australia;

<sup>6</sup>Department of Chemistry and Biomolecular Sciences, Macquarie University, New South Wales 2109, Australia;

<sup>7</sup>Department of Biology and Molecular Biotechnology Program, Centre for Cell and Developmental Biology, the Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China;

<sup>8</sup>Cincinnati Children's Hospital Medical Center, Division of Human Genetics, Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA;

<sup>9</sup>Department of Medical Genetics, University of British Columbia, Children's and Family Research Institute, 950 W 28<sup>th</sup> Ave., Vancouver, BC, Canada.

<sup>1</sup>For correspondence. Tel: 778-782-3982; Fax 778-782-3496; Email: [Kermode@sfu.ca](mailto:Kermode@sfu.ca)

Supplementary data is included; Supplementary figures: Fig. S1 and Fig. S2.

## Abstract

There is a clear need for efficient methods to produce protein therapeutics requiring mannose-termination for therapeutic efficacy. Here we report on a unique system for production of active human lysosomal acid  $\beta$ -glucosidase (glucocerebrosidase, GCase, EC 3.2.1.45) using seeds of the *Arabidopsis thaliana cgl* mutant, which are deficient in the activity of *N*-acetylglucosaminyl transferase I (EC 2.4.1.101). Gaucher disease is a prevalent lysosomal storage disease in which affected individuals inherit mutations in the gene (*GBA1*) encoding GCase. A gene cassette optimized for seed expression was used to generate the human enzyme in seeds of the *cgl* (C5) mutant, and the recombinant GCase was mainly accumulated in the apoplast. Importantly, the enzymatic properties including kinetic parameters,  $IC_{50}$  of isofagomine (IFG), and thermal stability of the *cgl*-derived GCase were comparable to those of imiglucerase, a commercially-available recombinant human GCase used for enzyme replacement therapy in Gaucher patients. N-glycan structural analyses of recombinant *cgl*-GCase showed that the majority of the N-glycans (97%) were mannose-terminated. Additional purification was required to remove the ~15% of the plant-derived recombinant GCase that possessed potentially immunogenic (xylose- and/or fucose-containing) N-glycans. Uptake of *cgl*-derived GCase by mouse macrophages was similar to that of imiglucerase. The *cgl* seed system requires no addition of foreign (non-native) amino acids to the mature recombinant GCase protein, and the dry transgenic seeds represent a stable repository of the therapeutic protein. Other strategies that may completely prevent plant-like complex N-glycans are discussed, including use of a null *cgl* mutant.

**Key words:** *Arabidopsis cgl* mutant, Gaucher disease, human glucocerebrosidase, mannose-terminated N-glycans, N-glycosylation,

## Introduction

Transgenic plants, seeds and cultured plant cells are potentially one of the most economical systems for large-scale production of recombinant proteins for industrial and pharmaceutical uses (Kermode 2006; Lau and Sun 2009; Kermode 2011). Seeds are particularly attractive as production hosts due to their high rates of protein synthesis during seed maturation, and their ability to remain viable in the mature dry (quiescent) and stored state (Twyman et al. 2003; Stoger and Ma 2005). The stability of proteins in dry seeds allows for the additional advantage of a ‘decoupling’ of the processing of the materials to obtain the purified recombinant protein from the generation and harvesting of the transgenic seeds (Boothe et al. 2010).

Over one-third of approved pharmaceutical proteins are glycoproteins (Saint-Jore-Dupas et al. 2007; Gomord et al. 2010), and even minor differences in N-glycan structures can change the distribution, activity or longevity of recombinant proteins as compared to their native counterparts, altering their efficacy as therapeutics. Thus, one of the major challenges of using plants as systems for pharmaceutical glycoprotein production is to produce these pharmaceuticals with ‘humanized’ N-glycans. Notably, certain processes of N-glycosylation that occur in post-ER compartments are markedly different in plant cells versus mammalian cells. Although the early steps and components of the N-glycosylation process in the ER (including the involvement of the dolichol lipid intermediate and ER oligosaccharide transferase), and the Golgi-localized *N*-acetylglucosaminyl transferase I (GnT I), are the same in plant and mammalian cells, differences occur during later stages as proteins transit through the Golgi complex (Lerouge et al. 1998). For example, in the plant Golgi complex, enzymes convert the original high-mannose N-glycans of proteins to plant-specific hybrid and complex N-glycans by a series of sequential reactions that rely on the accessibility of the glycan chain(s) to the Golgi

processing machinery (Kermode 1996; Gomord and Faye 2004). Plant-specific sugars that are associated with these ‘matured’ N-glycans, such as  $\beta$ -1,2-xylose and  $\alpha$ -1,3-fucose, may induce immune responses in humans, particularly when plant-made pharmaceutical glycoproteins are parenterally-administrated (Gomord et al. 2010).

Several strategies have been developed to reduce or eliminate plant-specific N-glycan maturation, including ER retention, targeting the protein of interest to protein storage vacuoles via a pathway that bypasses the Golgi complex, or by knocking out the genes that specify xylosyltransferase and fucosyltransferase activities (Kermode 2011). Another approach is to use the *Arabidopsis thaliana cgl* (complex glycan deficient) mutant, which lacks *N*-acetylglucosaminyl transferase I (GnT I) activity due to a mutation in the gene encoding GnT I (von Schaewen et al. 1993; Strasser et al. 2005). GnT I is the first enzyme in the pathway of hybrid and complex N-glycan biosynthesis. Without the addition of *N*-acetylglucosamine to the trimmed glycan, xylosyl- and fucosyl-transferases are unable to add  $\beta$ -1,2-xylose and  $\alpha$ -1,3-fucose, respectively. Thus, the N-glycans on endogenous proteins synthesized in this mutant are in the ‘high-mannose’ or oligomannosidic form, predominantly Man5-GlcNAc<sub>2</sub>, with minor amounts of Man6, Man7 and Man8.

Gaucher disease is a prevalent human lysosomal storage disease and it is caused by a hereditary deficiency of the lysosomal enzyme acid  $\beta$ -glucosidase (glucocerebrosidase, GCase, EC 3.2.1.45). GCase catalyzes the hydrolysis of the glycosphingolipid, glucocerebroside (glucosylceramide) to generate glucose and ceramide (Beutler and Grabowski 2001). The disease has been broadly defined as three major clinical subtypes (1, 2, and 3), with type 1 representing non-neuronopathic disease and types 2 and 3 neuronopathic disease (Grabowski 2008). Progressive accumulation of glucocerebroside in the lysosomes of macrophages in various

tissues of the reticuloendothelial system leads to visceral organ manifestations, which are common to all Gaucher disease subtypes (Grabowski 1997). The visceral manifestations of Gaucher disease can be treated by enzyme replacement therapy (ERT). The current FDA approved ERT is imiglucerase, a recombinant human GCCase produced in Chinese hamster ovary (CHO) cells (Cerezyme®; Genzyme Corp., MA, USA). After its expression and purification, imiglucerase is modified by treatment with three glycosidases ( $\alpha$ -neuraminidase,  $\beta$ -galactosidase, and  $\beta$ -*N*-acetylglucosaminidase) (Furbish et al. 1981; Bijsterbosch et al. 1996; Friedman et al. 1999) to expose the terminal mannose residues on the N-glycans of the recombinant GCCase. These terminal mannose sugars are recognized by the mannose receptor located on the macrophage plasma membrane; this downstream processing of GCCase improves its targeting to and internalization by macrophages. The annual average cost for each patient ranges from 125,000 to more than 500,000 USD (Schmitz et al. 2007).

Here, active human GCCase was produced in seeds of an *Arabidopsis thaliana cgl* mutant. The enzymatic properties including kinetic parameters,  $IC_{50}$  of isofagomine and thermal stability of *cgl*-derived GCCase are similar to those of imiglucerase. The major N-glycan components of the recombinant GCCase were of the oligomannosidic type (85%), with the remainder being complex and hybrid types (15%). Mannose-terminated N-glycans represented 97% of the N-glycans on the *cgl*-GCCase. The addition of a purification step (an anti-horseradish peroxidase affinity column) effectively removed the recombinant GCCase containing xylose and/or fucose.

The present strategy demonstrates the potential for producing appropriate recombinant therapeutics if a null *cgl* mutant is used (e.g. the *cglI* C6 mutant; see Discussion), or after extensive purification of the proteins to remove antigenic (complex/hybrid N-glycan) forms of the enzyme.

The uptake of *cgl*-derived GCCase into mouse macrophages was similar to that of imiglucerase. Two advantages that may render the present system a viable alternative for GCCase production for ERT include: (1) a three-step (*in vitro*) enzymatic processing of *cgl*-GCCase is not needed to generate mannose-terminated glycans, which contrasts with CHO-cell-derived GCCase; and (2) there is no need for additional amino acids on the mature recombinant GCCase protein, as is the case for the carrot cell-derived GCCase for targeting of the enzyme to a protein-storage-vacuole destination (Shaaltiel et al. 2007).

## Results

### *Recombinant human GCCase of cgl seeds is active*

The regulatory sequences of the seed protein gene *arcelin 5-I* (*ARC5-I*; accession no. Z50202) of the common bean (*Phaseolus vulgaris*) are very effective in enhancing heterologous gene expression in plants, including *Arabidopsis* and tobacco (Goossens et al. 1999; De Jaeger et al. 2002; Kermodé et al. 2007). In addition, the sequence encoding the arcelin signal peptide combined with the arcelin promoter, 5' UTR, and 3' flanking regions of the arcelin gene synergistically enhance recombinant human  $\alpha$ -L-iduronidase expression in *Arabidopsis thaliana* *cgl* seeds (Downing et al. 2006; Downing et al. 2007; reviewed in Kermodé 2006). Here, these sequences were employed to achieve high-level production of the human recombinant GCCase. The construct (Fig. 1A) was transformed into plants using the floral dip method of *Agrobacterium*-mediated gene transfer (Clough and Bent 1998) and T<sub>2</sub> generation seeds were collected from 43 plants. Proteins were extracted from these seeds and screened for GCCase activity. Some background activity was present in the untransformed *cgl* seeds (Fig. 1B), presumably due to endogenous enzymes that can hydrolyze the artificial substrate. This was

confirmed by treatment of the transgenic seed extracts from line 1 with the inhibitor conduritol B epoxide, in which the fraction of activity that was sensitive to this GCCase-specific inhibitor was 92%. The transgenic lines showed variable GCCase activity above or near this background level. One transgenic line had high GCCase activity ( $24.0 \pm 1.8$  units/mg total soluble protein [TSP]; Fig. 1B). Western blot analysis (Fig. 1C) of seed extracts from a subset of the transgenic lines shown in Fig. 1B indicated a ~60 kDa protein which was detectable at variable levels. The line with the highest level of GCCase activity showed the highest accumulation of GCCase protein. There was no cross reactivity of the GCCase polyclonal antibody with any endogenous proteins in untransformed *cgl* seeds (Fig. 1C, UT).

#### *GCCase of cgl storage parenchyma cells is secreted*

To determine the subcellular localization of GCCase, immunolabeling was carried out on ultra-thin sections of *cgl* seeds prepared from high-pressure freezing/frozen substitution of the tissues. The sections were sequentially incubated with anti-GCCase antibody, and then with gold-conjugated secondary antibody. Sections of the untransformed *cgl* seeds were used as negative controls. Electron micrograph images of the transgenic seed sections indicate that the gold particles were predominantly present within the extracellular spaces (Fig. 2), indicating that most of the GCCase was secreted into the apoplast, as expected.

#### *Properties of purified cgl-derived GCCase are comparable to those of imiglucerase*

To further characterize the *cgl*-derived GCCase, the enzyme was purified by a three-step procedure that used Con A chromatography, Butyl FF chromatography and Bio-Gel P 100 chromatography (Table I). The purified GCCase was resolved by SDS-PAGE and stained with Coomassie Brilliant Blue. After destaining, a single band on the gel indicated that GCCase was purified to homogeneity (Fig. 3). The diffuse nature of the band was suggestive of variation in

the pattern of N-glycosylation/N-glycan maturation of GCase. There are five consensus sites for N-glycosylation on GCase (Asn-X-Ser/Thr); generally four sites are utilized in mammalian cells (Berg-Fussman et al. 1993; Jonsson et al. 1987; Bergmann et al. 1989), and most of the N-glycans are in complex forms (see Discussion).

Kinetic analyses were carried out to compare *cgl*-GCase and imiglucerase using the fluorogenic substrate 4-MUGP. *Cgl*-GCase and imiglucerase exhibited similar  $V_{\max}$  and  $K_m$  values (Fig. 4 and Table II). Isofagomine (IFG) is a potent inhibitor of GCase (Lieberman et al. 2007). The  $IC_{50}$  values of IFG for the two enzymes were also similar (Table 2). The  $IC_{50}$  value of IFG for imiglucerase at pH 5.2 using the same substrate was reported as 30 nM (Steet et al 2006). A fluorescence denaturation assay was used to determine the thermal stability of both enzymes, as characterized by the melting temperature ( $T_m$ ) in the presence and absence of IFG. Significantly, the melting temperatures of *cgl*-GCase and imiglucerase in the absence or presence of 300  $\mu$ M IFG were similar (Table II). These results demonstrate that *cgl*-GCase and imiglucerase have similar enzymatic properties.

*N-glycans of cgl-derived GCase are mannose-terminated and predominantly oligomannosidic*

Purified GCase from *cgl* seeds was analyzed for its constituent N-glycans by carbon LC ESI MS/MS. The results show that ~85% of the N-glycan components detected were of the oligomannosidic type (i.e. those containing 1-7 hexose residues in addition to the pentasaccharide N-glycan core). The remaining 15% were paucimannose and hybrid N-glycans containing xylose and/or fucose (Fig. 5 and Table III). Man5-type glycans accounted for ~60%. Structures like Man5F are indicative of exoglycosidase activities on the N-glycans during expression and/or purification of the protein. The N-glycans possessing terminal mannose residues accounted for ~97%. Since 15% of the *cgl*-GCase possessed potentially immunogenic

hybrid/complex N-glycans, we investigated a method to remove the recombinant proteins possessing xylose- and/or fucose-containing N-glycans. A purification step implementing an anti-horseradish peroxidase column was conducted; this step was effective in removing the recombinant proteins containing matured N-glycans (Fig. 6).

*The efficiency of mouse macrophages to internalize cgl-GCase and imiglucerase via their cell-surface mannose receptors is comparable*

Mouse macrophage cells (RAW 264.7) were used to determine the efficiency of GCCase uptake. Equal amounts of *cgl*-GCCase and imiglucerase ( $3000 \pm 300$  nmoles MU/h,  $\sim 1 \mu\text{g}$ ) were applied to the RAW cells (Fig. S1, A). Following the 3-h incubation period, total intracellular GCCase activity was determined and found to be significantly increased ( $\sim 20\%$ ) in cells treated with *cgl*-GCCase and imiglucerase relative to untreated cells (Fig. S1, B). To reduce the high endogenous murine GCCase activity in RAW cells, an antibody that specifically recognizes human GCCase was used to “pull down” and directly measure the increase in enzyme activity produced by the internalized imiglucerase or *cgl*-GCCase. This procedure resulted in a 300-fold reduction in background levels of murine GCCase activity relative to cells that were treated with either of the recombinant GCCase proteins (Fig. 7). Importantly, similar amounts of imiglucerase and *cgl*-GCCase were internalized by the cultured macrophages. Furthermore, the internalization of either enzyme was similarly reduced by  $\sim 7$ -fold when yeast mannan was included in the culture media. These data indicate that the major cellular mechanism of endocytosis is the same for either form of GCCase, i.e., via mannose receptors expressed on the plasma membrane of macrophages. As has been demonstrated by the efficacy of imiglucerase when used for enzyme replacement therapy, following receptor-mediated endocytosis the receptor-ligand complex is transported to the lysosome where GCCase can hydrolyze its stored substrate.

*GCase is moderately stable during seed storage.*

To determine the post-harvest stability of GCase, seeds were harvested when siliques had dried out (three weeks after pollination). These seeds were maintained at room temperature for 25 d for further drying (seeds lost fresh weight during the first 2 weeks), and were then transferred to 4 °C, during which time they were maintained over silica gel as a desiccant (Table IV). The GCase activities declined during the initial storage period when seeds were kept at room temperature but the activities recovered following the transfer of seeds to 4 °C within two months. At the end of the storage period (at d 115 of storage) the GCase activities were about 75% of the original. Interestingly, the pattern showing a transient increase in GCase activities following the transfer of seeds to 4 °C storage conditions is also observed for another lysosomal hydrolase ( $\alpha$ -L-iduronidase) produced as a recombinant protein in *cgl* seeds (Downing et al. 2007). These data suggest that *cgl*-derived GCase is moderately stable during seed storage.

## **Discussion**

*GCase produced in cgl seeds is highly active and possesses similar characteristics to those of imiglucerase*

Arabidopsis seeds constitute an attractive host for the expression of complex therapeutic glycoproteins: (1) The seeds are not a food crop; thus regulatory issues are far less contentious (e.g. issues pertaining to a need to separate edible food crops destined for consumption, from those destined for biopharmaceutical use); (2) The stability of the recombinant protein in the mature dry cool-stored seeds (including GCase in the present study) is a significant advantage, and allows one to generate many seeds that can conveniently stored until the protein is required.

(3) Automated sowing/harvesting of pilled seeds for bulk production of Arabidopsis biomass has been developed or is in the process of being developed (Loos et al. 2011).

In the present study, the highest expressing *cgl* line of Arabidopsis accumulated GCCase at a protein amount of ~0.1% TSP (T3 seeds). Using this line and our present purification protocol, one mg of purified GCCase can be generated from ~25-30 g of mature dry seed. There is likely the potential to obtain lines with even higher GCCase activity and protein levels with more screening; expression of human  $\alpha$ -L-iduronidase in *cgl* seeds using the same (arcelin gene) regulatory sequences, yielded an exceptional line in which the  $\alpha$ -L-iduronidase protein was estimated to be 18  $\mu$ g/mg TSP or 1.8% TSP (Downing et al. 2006; Downing et al. 2007).

Most importantly, the enzymatic properties of purified *cgl*-derived GCCase including kinetic parameters ( $V_{\max}$  and  $K_m$ ), thermal stability and  $IC_{50}$  of IFG were similar to those of imiglucerase.

*Cgl seeds generate GCCase with mannose-terminated N-glycans and the GCCase protein is efficiently sequestered by mammalian macrophages*

Immunogold EM localization of GCCase in transgenic Arabidopsis *cgl* seeds demonstrated that the majority of recombinant GCCase was secreted into the apoplast associated with embryo storage parenchyma cells. In human tissues, GCCase appears to be loosely associated with the lysosomal membrane (van Weely et al. 1990). In mammalian cells, GCCase is targeted to the lysosome independently of the mannose-6-phosphate receptor (Aerts et al. 1988); the lysosomal integral membrane protein LIMP-2 plays a specific role in this targeting process, and in its absence, the majority of GCCase is secreted (Reczek et al. 2007).

Since the transport pathway of GCCase to the plant cell surface most likely occurs via transit

through the Golgi complex, it was important to determine the maturation status of the N-linked glycans of the recombinant GCase. The recombinant GCase predominantly possessed oligomannose type N-glycans, with 60.2% Man5 and 17.4% Man4. The core fucosylated mannosidic Man5F and the Man3GnXF accounted for 3.1% and 2.7% of the N-glycans, respectively. Some of the paucimannosidic N-glycan structures (Man3) containing xylose and/or fucose accounted for ~9 % and may be generated by the action of vacuolar or plasma membrane  $\beta$ -N-acetylhexosaminidases (HEXO1 and HEXO 2/3, respectively) (Strasser et al. 2007). The immunogold EM analyses detected a minor fraction of the GCase in protein storage vacuoles of the *cgl* seeds (Fig. S2); most of the recombinant enzyme was secreted (Fig. 2). *Cgl*-GCase containing these N-glycan species likely initially contained a terminal GlcNAc residue (allowing for the addition of xylose and/or fucose in the plant Golgi, see below); subsequently the terminal GlcNAc may have been removed by one or more of the  $\beta$ -N-acetylhexosaminidases.

This study represents the first detailed analysis of the glycan profile of a human therapeutic glycoprotein generated within an Arabidopsis seed *cgl* background. The mutant is characterized by one amino acid change in N-acetylglucosaminyl transferase I (GnT I) (Asp<sup>144</sup> to Asn). This creates an additional N-glycosylation site that leads to a misfolded and unstable protein with no detectable enzyme activity (Strasser et al. 2005). Earlier reports of the *cgl* mutant showed an absence of complex glycans on glycoproteins of plant leaf extracts or callus extracts, with the predominant type of glycan being Man5GlcNAc<sub>2</sub> (von Schaewen et al. 1993; Strasser et al. 2005). More recently, Frank et al. (2008) in their analysis of three *cglI* alleles detected a low level of GnT I activity in this particular *cgl* mutant under conditions that promote ‘underglycosylation’ of proteins. For example, tunicamycin treatment relieves the ‘folding block’ for the mutant GnT I protein, permitting its transit to the Golgi complex. Thus, the conditional

nature of this particular *cgl* mutant (*cglI* C5) has been demonstrated. Partial restoration of GnT I activity during seed development is a distinct possibility in the *cglI* C5 mutant. Our glycan data on *cgl*-derived GCCase, showing ~15% of N-glycans containing xylose and/or fucose, suggests that this may indeed be the case. Glycan trimming appears to play a critical role during seed development (Boisson et al. 2001), and it is possible that complex N-glycans are likewise important. Conditional lethality of animal cells occurs when there is GnT I deficiency. For example, deficiency of GnT I is an embryonic lethal in mice (Ioffe and Stanley 1994), whereas CHO cell mutants that lack GnT I activity are healthy (Kumar et al. 1990). The present strategy demonstrates the potential for producing appropriate recombinant therapeutics, including GCCase, if the *cglI* C6 mutant is used, as this line is a true loss-of-function mutant. Alternatively, extensive purification of the *cglI* C5-derived proteins to remove antigenic forms of the enzyme could be implemented. For example, we show that a chromatography step in the purification scheme is an effective means to remove the ~15% complex/hybrid-glycan-containing CGase (see later discussion).

N-glycosylation (e.g. at Asn-19) is critical for the acquisition of GCCase activity (Berg-Fussman et al. 1993). There are five predicted N-glycosylation sites in GCCase; the first four of them are generally utilized (Berg-Fussman et al. 1993). Sequential *in vitro* enzymatic remodeling of the three complex N-glycans of placental GCCase to “uncover” terminal mannose residues, generates a modified GCCase that is more efficiently internalized by macrophages because of its improved ability to interact with mannose receptors on macrophages (Furbish et al. 1981). This strategy was used to modify the N-glycans on CHO-cell-derived recombinant human GCCase, imiglucerase (in which the N-glycans are predominantly complex types at all four sites), and the remodeled imiglucerase showed increased clinical efficacy for Gaucher disease (Grabowski et al.

1995). To eliminate the need for carbohydrate remodelling, alternative expression systems that generate GCCase with mannose-terminated N-glycans *in vivo* have attracted attention, such insect cells (Sinclair and Choy 2002), *Lec1* mutant CHO cells (Van Patten et al. 2007) and kifunensine (mannosidase I inhibitor)-treatment of a cultured human cell line induced to produce gene-activated human GCCase ('velaglycerase alfa') (Brumshtein et al. 2010).

Plant-based systems are viewed as one of the more promising alternative expression systems for cost-effective production of recombinant proteins, possessing distinct advantages, even over the above-mentioned systems. However, the sugars that are added during N-glycan maturation (i.e. formation of complex glycans), such as  $\beta$ -1,2- xylose and  $\alpha$ -1,3-fucose, may pose problems in part because of their potential immunogenicity, and this has limited the use of plant systems for production of human therapeutic proteins. GCCase has been expressed in tobacco leaves, tobacco seeds and carrot suspension cells (Reggi et al. 2005; Shaaltiel et al. 2007). GCCase derived from tobacco seeds is problematic since terminal mannose residues account for only a small proportion of the N-glycans on tobacco-expressed recombinant GCCase; uptake of this protein by human R120W fibroblasts was 5-fold lower when compared to imiglucerase. Shaaltiel et al. (2007) used carrot suspension cells to express a modified human GBA cDNA, whereby the recombinant GCCase was targeted to storage vacuoles by appending a vacuolar targeting sequence. Because of the glycosidases that are resident in the protein storage vacuole, recombinant human GCCase with mannose-terminated N-glycans was produced. The recombinant GCCase expressed in carrot cells was shown to contain over 90% mannose-terminated N-glycans, and to exhibit the same rate of uptake by thioglycolate-elicited peritoneal macrophages as imiglucerase. It is noteworthy that the recombinant enzyme produced in this expression system has two modifications that may be of concern relative to *cgl*-GCCase and imiglucerase. Firstly,

the mature recombinant GCCase protein has two extra amino acids on the N-terminus (derived from the linker used for the fusion of a plant-specific signal peptide; EF), and seven extra amino acids on the C-terminus (DLLVDTM - constituting the vacuolar sorting determinant of tobacco chitinase A) (Neuhaus et al. 1991). Secondly, the dominant N-glycans contain xylose and/or fucose residues, which are potentially antigenic structures. Although a single-dose test did not lead to any toxic responses in mice (Shaaltiel et al. 2007), and a subsequent primate study uncovered no adverse effects (Aviezer et al. 2009), the United States Federal Drug Agency, nonetheless, has requested further testing of this carrot cell-derived therapeutic. As a potential plant-based ERT for Gaucher disease, *cgl*-GCCase does not share these concerns.

We have shown that GCCase produced in the *cgl1* C5 background of Arabidopsis naturally contains mannose-terminated N-glycans (97%) that are predominantly oligomannosidic (85%). This obviates the need for further *in vitro* enzymatic remodeling. However, the xylose- and/or fucose-containing recombinant *cgl*-GCCase molecules (comprising ~15%) need to be removed. One strategy, as demonstrated here, is to remove this fraction using an anti-horseradish peroxidase affinity column as one of the purification steps. It may be preferable to perform this step prior to a final Bio-gel filtration step; this would avoid any IgG leaching from the affinity column (and therefore potentially introducing immunogenicity). Another strategy is to host production of the recombinant protein in the null *cgl* (C6) mutant.

Thus the *cgl* system provides proof-of-principle of a viable plant-based expression platform to produce recombinant GCCase with mannose-terminated N-glycans. Macrophage uptake studies confirmed that *cgl*-GCCase was taken up to a similar extent as imiglucerase, and primarily via mannose receptors. Both *cgl*-GCCase and imiglucerase have similar enzyme kinetic and thermostability properties. These results provide the foundation for future experiments to

evaluate the *in vivo* stability and therapeutic efficacy of Arabidopsis-derived GCCase to reduce substrate storage in our murine model of Gaucher disease (Sinclair et al. 2007).

## Materials and Methods

### *Generation of the expression construct for production of recombinant human GCCase, and generation of Arabidopsis transformants*

Procedures for DNA manipulation were conducted according to standard protocols (Sambrook et al. 1989) using enzymes from Fermentas Canada Inc. (Burlington, ON, Canada) and Invitrogen Life Technologies (Burlington, ON, Canada). Oligonucleotide primers for PCR amplification reactions were synthesized by Sigma-Genosys ([www.sigma-genosys.com](http://www.sigma-genosys.com)); PCR-generated sequences were confirmed by sequence analysis (University Core DNA and Protein Services, University of Calgary, Calgary, AB, Canada).

The planned sequence of ligations required, in one instance, the elimination of a single *EcoRI* site and, in another, elimination of *HindIII* and *EcoRI* sites from the plasmid used in the majority of the subcloning, pT7T3 18u. This was accomplished by cutting with the respective restriction enzymes and filling in with Klenow fragment. The resulting plasmids were designated pTE and pTHE, respectively.

A PCR reaction was performed to take advantage of the unique *MfeI* site near the 5' end of the GBA open reading frame and accomplish the dual goal of adding an *EcoRI* site and excising a *HindIII* site. The DNA sequence encoding the 5' end of the human GBA cDNA was PCR-synthesized using pBS-GC1.6/E5 as template, with the forward primer p(9) containing the new *EcoRI* site (5'-CCATCGATGAATT CCTGGCGATGCCACAGGTA-3') and the reverse primer P(10) comprised of 5'-AGGACCCAATTGGGTGCGT-3'. After restriction of the PCR-

amplified product with *MfeI* and *ClaI*, the 323-bp fragment encoding the C-terminus of the mature GCase protein was isolated for cloning. The original plasmid containing the GBA cDNA (pBS-GC1.6/E5) was digested with *MfeI* and *ClaI*, treated with calf intestinal alkaline phosphatase and purified. Re-integration with the digested and phosphorylated PCR fragment led to the generation of the new plasmid pBS-GC *Cla/Mfe*.

Two PCR reactions were performed to generate two fragments, which are denoted A and B (Fig. 1A). For A, a fragment containing DNA regulatory sequences of the arcelin gene (the *ARC 5-I* gene promoter, and 5'-UTR and signal peptide-encoding sequences) was PCR-synthesized using pWD 66 (Downing et al. 2006) as a template, forward primer p(1) (5'-ACGCCCCGGGG TTATTCCTCATCACCAGAC-3') and reverse primer p(2) (5'-TGAGTTTGC GTGTGTGAGAA-3'). For B, the DNA sequence encoding the 5' end of the GBA open reading frame (minus its signal peptide-encoding sequences) was PCR-synthesized using pBS-GC1.6/E5 as template, forward primer p(3) (5'-GCCCCCCCCTGCATCC-3') and reverse primer p(4)(5'CGCGTCTAGAGGGTACCCGGATGATGTTAT-3'). After restriction of the PCR-amplified products (A with *XmaI*, and B with *HindIII*) the fragments were isolated, phosphorylated and purified for cloning. The two fragments were ligated into pTHE (which had been digested with *XmaI* and *HindIII*, treated with calf intestinal alkaline phosphatase and purified on an agarose gel), giving rise to pTHE AB for later cloning.

The DNA sequence encoding the C-terminus of the GCase protein was PCR-synthesized using pBS-GC *Cla/Mfe* as template, forward primer p(14) (5'-CCCTAAAAGCTTCGGCTACA-3') and the reverse primer p(15) (5'-TCACTGGCGATGCCACAGGTA-3'). The DNA sequence comprising the 3' end of the arcelin gene was released from pWD66 (Downing et al. 2006) by restriction digestion with *XbaI*. Both fragments were gel-purified and ligated to generate pTECD.

To make the final construct for production of GCase in *cgl* seeds (Fig. 1 A), pTECD was digested with *Hind*III and *Xba*I, and the fragment gel-purified and ligated into pTHE AB generating pTHE ABCD. The *Xma*I/*Xba*I fragment from the pTHE ABCD was recovered from the gel and ligated into the binary vector pRD 400 *Xma*I/*Xba*I site. Plasmid pRD400 carries the NPTII gene for kanamycin resistance (Datla et al. 1991).

The recombinant binary plasmid was introduced into competent *Agrobacterium tumefaciens* GV3101/pMP90 cells (Koncz and Schell 1986) according to Katavic et al. (1994). Transformed cells were selected on media containing 50 µg/ml kanamycin, 25 µg/ml rifampicin and 25 µg/ml gentamycin.

*Arabidopsis thaliana cgl* seeds were obtained from the Arabidopsis Biological Resource Center (stock number CS6192). This particular mutant is referred to as *cgl* C5 in Frank et al. (2008). Arabidopsis plants were transformed according to the floral dip method described by Clough and Bent (1998). T<sub>1</sub> generation transformants were selected on medium containing 50 µg/ml kanamycin according to Katavic *et al.* (1994). Plants were grown at 20 °C in long days (16 h light, 8 h dark; 90 to 120 µE·m<sup>-2</sup>·sec<sup>-1</sup> PAR) on prepared soil mix (Terra-Lite Redi Earth; W.R. Grace and Company of Canada Ltd., Ajax, ON, Canada). Seeds of the T<sub>2</sub> generation were used for screening (western blot analyses and GCase activity assays). Seeds of the T<sub>3</sub> generation of the highest expressing line were used for GCase purification.

#### *GCase activity assays*

GCase activities in the crude extracts or purified fractions were assayed using the fluorogenic substrate 4-methylumbelliferyl β-D-glucopyranoside (4-MUGP) (Sigma) according to Sawkar et al. (2002) and Dale and Beutler (1976). Protein was extracted from *cgl* seeds by grinding seeds with a plastic pestle in buffer (50 mM sodium phosphate, pH 6.0, 0.1% sodium taurocholic acid,

1 mM EDTA, 0.5 mM PMSF). The homogenate was centrifuged at 13,000 rpm for 10 min and the resulting supernatant was assessed for GCCase activity and total soluble protein (quantitative) assays. The activity assay was carried out by adding 5  $\mu$ l of protein extract to 50  $\mu$ l of the assay buffer containing 0.1 M potassium phosphate (pH 5.0), 0.15% Triton, 0.125% sodium taurocholate and 1.5 mM 4-MUGP. The mixture was incubated at 37° C for 0.5-1 h and terminated by adding 1.4 ml glycine buffer (0.2 M glycine, 0.125 M sodium carbonate, pH 10.7). Fluorescence of the reaction product, 4 MU, was determined ( $\epsilon_{\text{ex}} = 365 \text{ nm}$ ,  $\epsilon_{\text{em}} = 460 \text{ nm}$ ). One unit of activity is defined as the amount of enzyme required to release 1 nmol 4 MU/min. Protein concentrations were determined by the Bio-Rad DC assay (Bio-Rad Laboratories Inc.).

#### *Western blot analysis*

The alkaline phosphatase detection system was used for western blots to identify the transgenic *cgl* lines producing recombinant GCCase using methods described previously (24). The primary polyclonal anti-GCCase antibody (Grabowski et al. 1985) was diluted 1:1000. Purified *cgl*-GCCase was subjected to western blot analysis, before and after passage through an anti-horseradish-peroxidase affinity column, to detect the GCCase proteins that contained plant-specific complex N-glycans. (see below). For these analyses the Lumigen™ TMA-6 detection kit was used as per the manufacturer's instructions (GE Healthcare UK Limited, Little Chalfont Buckinghamshire, UK). The anti-complex glycan antibody (Lauriere et al. 1989) was diluted 1:2000.

#### *Immunogold electron microscopy (EM) localization of GCCase*

The general procedures for immunogold EM studies to localize GCCase in transgenic *cgl* seeds were performed essentially as described previously (Tse et al. 2004). Dry seeds of untransformed *cgl* and transgenic *cgl* plants were imbibed in water at 4 °C for 12 h before high-pressure freezing, and subsequent substitution of frozen sections with hydrophobic Lowicryl resin HM20.

Immunolabeling was carried out using GCCase-specific polyclonal antibodies at a 1:300 dilution and gold-coupled secondary antibodies at a 1:50 dilution. Aqueous uranyl acetate/lead citrate poststained sections were examined in a JOEL JEM-1200EX II transmission electron microscope (JOEL, Tokyo, Japan) operating at 80 kV.

#### *Purification of GCCase from cgl seeds*

The purification protocol was developed based on Furbish et al. (1977), Dale and Beutler (1976), Choy (1989), and Lee et al. (1994). Seeds of the T3 generation (line no. 1) were ground in liquid N<sub>2</sub> and proteins were extracted using the following buffer: 20 mM Tris, pH 7.0, 150 mM NaCl, 0.5% taurocholic acid, 1 mM PMSF. The conditions for concanavalin A (Con A) column binding and elution were optimized to facilitate maximum binding and elution of GCCase (based on activity assays). After centrifugation at 15,000 rpm for 45 min, the supernatant was collected and loaded onto a Con A-sepharose column using a peristaltic pump (Pump-P1, Amersham) recycling for 24 h at 4 °C. After washing, glycoproteins were eluted from the column using 15% methyl- $\alpha$ -mannoside in the above buffer recycling for 16-24 h with four exchanges of elution buffer. The eluant was concentrated using Microcon 30 kDa (Amicon) (Millipore, Billerica, MA, USA) and an exchange buffer with 100 mM sodium acetate, pH 5.2, 14% (w/v) ammonium sulfate (buffer A). The concentrated eluant was filtered through a 0.45- $\mu$ m filter and loaded onto a Butyl FF column (1 ml; GE Healthcare Life Science, Quebec, Canada) using ÄKTA<sup>TM</sup>FPLC<sup>TM</sup> (GE Healthcare Life Science, Quebec, Canada) at a flow rate of 0.5 ml/min. The column was then washed with 15 ml buffer A and 15 ml 50 mM ammonium sulfate followed by 15 ml of 24% ethanol (v/v) in 100 mM acetate buffer, pH 6.0. The GCCase was then eluted with an elution buffer (150 mM acetate buffer, pH 6.0 containing 36% ethanol v/v; final pH 6.5). The eluted fractions were collected and assayed for GCCase activity, and active fractions were pooled and

concentrated with Microcon 30 kDa. The concentrated eluant was diluted 1:1 with 150 mM acetate buffer (pH 6.0) and loaded onto a Bio-Gel P 100 (BioRad) column (2.5x15 cm). GCCase was eluted with 150 mM acetate buffer, pH 6.0 containing 18% ethanol at a flow rate of 0.5 ml/min. Fractions with GCCase activity were concentrated with Microcon 10 kDa, then fractionated by SDS-PAGE to examine the purity of GCCase. For long-term storage, the purified GCCase fractions were combined and then dialyzed in 0.1 M citrate buffer, pH 6.0 containing 50% ethylene glycol.

#### *Thermal denaturation experiments*

The thermal stabilities of imiglucerase and *cgl*-GCCase in the presence or absence of 300  $\mu$ M IFG (isofagamine tartrate; Toronto Research Chemicals, North York, Canada) were evaluated using the previously described fluorescence denaturation assay based on the environmentally sensitive fluorophore NanoOrange (Kornhaber et al. 2008). All assays were performed in 100 mM phosphate 50 mM citric acid buffer at pH 7 in the presence of 1  $\mu$ g *cgl*-GCCase/imiglucerase and a 1/100 dilution of NanoOrange stock (Invitrogen). Thermal denaturation was carried out using a Mini-Opticon RT PCR (BioRad) instrument. Melting temperatures ( $T_m$ ) of enzymes in the presence or absence IFG were determined using the software provided by supplier.

#### *Kinetic evaluation of GCCase derivatives*

Activities of enzymes were evaluated at pH 5.5 in 200 mM sodium phosphate 100 mM sodium citrate buffer containing 0.2% taurodeoxycholate at 37°C as described previously (Tropak et al. 2008). The half-maximal inhibitory concentration ( $IC_{50}$ ) of IFG (isofagamine tartrate) for imiglucerase or *cgl*-GCCase was determined in the presence of 5 mM 4-MUGP substrate.  $K_m$  and  $V_{max}$  values for *cgl*-GCCase and imiglucerase were determined in the presence of a two-fold dilution series of decreasing concentrations of substrate (10 mM to 0.3 mM). Values were

determined following nonlinear fitting of the data using the Michaelis-Menten equation within Prism 5.0.

#### *Glycan composition analyses*

The graphitized carbon liquid chromatography tandem mass spectrometry (carbon LC MS/MS) system was used to characterize the N-glycan status of recombinant GCCase (Wilson et al. 2002). Purified GCCase (4  $\mu$ g) was resolved by 10% SDS-PAGE and the GCCase protein band was recovered from the gel. N-glycans were released using PNGase A from tryptic peptides obtained after in-gel digestion as described by Kolarich and Altmann (Kolarich and Altmann 2000). The released N-glycans were reduced and desalted and were analyzed by carbon LC ESI MS/MS using a Thermo Hypercarb column (180  $\mu$ m ID x 100 mm) with an Agilent 1100 capillary LC and an Agilent ion trap for detection using negative ion mode according to Wilson et al. (2002). Oligosaccharide structures were assigned based on mass, MS/MS fragmentation and on the knowledge about plant N-glycosylation synthetic pathways (Leonard et al. 2004). The relative N-glycan distribution was calculated from the signal intensities of the monoisotopic m/z signals in the combined MS spectrum, which was summed over the entire range in which the N-glycans elute. If the singly and doubly charged signals were detected, both intensities were taken into account.

#### *Anti-horseradish-peroxidase affinity column for removal of GCCase containing plant complex N-glycans*

Approximately 15% of the GCCase derived from *cgl* seeds contained matured N-glycans, i.e., N-glycans with xylose and/or fucose. This fraction of the GCCase was removed from the sample by passing the purified GCCase (a single band on SDS-PAGE) through an anti-horseradish-peroxidase affinity column (recycling overnight at 4°C). The antibody specifically binds to

xylose and/or fucose residues (Wilson et al. 1998), allowing for the removal of any GCCase containing these sugars from the sample. The polyclonal anti-horseradish-peroxidase antibodies (Sigma-Aldrich Canada, Oakville, Ontario, Canada) were cross-linked to Affi-Gel 10 (Bio-Rad Laboratories Inc., Mississauga, ON, Canada) according to the manufacturer's instructions.

#### *Uptake of GCCase by mouse macrophages*

GCCase uptake experiments were conducted according to a protocol of Brumshtein et al. (2010) with modifications. RAW 264.7 mouse macrophage cells were distributed into 24-well plates ( $0.5 \times 10^5$  cells/well) and grown in RPMI (Roswell Park Memorial Institute) medium supplemented with 10% fetal calf serum overnight at 37°C in a CO<sub>2</sub> humidified incubator. The following day, the growth medium was removed, cells were washed twice with phosphate buffered saline (containing calcium and magnesium) and replaced with RPMI growth media supplemented with 0.025% human serum albumin (RPMIH) or RPMIH containing 20 mg/ml yeast mannan (RPMIHM). Following a 1-h incubation at 37°C, the corresponding buffers were substituted with fresh buffer containing equivalent activity units of GCCase (~ 1 µg, 3000 nmoles MU/h units of imiglucerase [Genzyme, USA] or *cgl*-GCCase), or lacking enzyme. Prior to the incubation period, an aliquot was removed to confirm the amount of units of enzyme added. Uptake was allowed to proceed for 3 h at 37 °C in a CO<sub>2</sub> humidified incubator. Following uptake, the incubation buffer was removed and the cells were extensively washed with 3 changes of phosphate buffered saline containing calcium and magnesium (2 ml). Cells were lysed at 4°C for 30 min using 200 µL citrate phosphate (McIlvaine) buffer pH 5.5 containing 0.4% Triton X 100 and 0.2% taurodeoxycholate. One fifth of the lysate was used to measure total intracellular GCCase and β-N-acetyl hexosaminidase activity as described previously (Tropak et al. 2008). The remainder of the lysate was used to immunoprecipitate endocytosed recombinant human GCCase

(imiglucerase or *cgl*-GCCase). To each lysate sample was added 1  $\mu$ l of rabbit anti-human GCCase (Tropak et al. 2008) together with 20  $\mu$ l of a 50% slurry of GammaBind™ Plus Sepharose™ beads (GE Healthcare, USA). Binding was allowed to proceed overnight with end-over-end mixing. Beads were then spun down by brief centrifugation, followed by three washes with 200  $\mu$ l lysis buffer. The majority of wash buffer was removed and replaced with 25  $\mu$ l lysis buffer followed by an equal volume of 4-MUGP (to give a final concentration of 5 mM) in McIVaine buffer pH 5.5. Reactions were carried out for 1 h at 37°C and monitored as described previously (Tropak et al. 2008).

### **Funding**

This work was supported by a Natural Sciences and Engineering Research Council of Canada (NSERC) Strategic grant (STPGP 350770-07) and a Michael Smith Foundation for Health Research (MSFHR) Senior Scholar Investigatorship awarded to ARK.

### **Abbreviations**

The abbreviations used are: *cgl*, *complex-glycan-deficient*; concanavalin A, Con A; EM, electron microscopy; GBA gene, *GBA1* gene encoding glucocerebrosidase; GCCase, glucocerebrosidase; IC<sub>50</sub>, half-maximal inhibitory concentration; IFG, isofagomine tartrate; 4-methylumbelliferyl  $\beta$ -D-glucopyranoside, 4-MUGP; *N*-acetylglucosaminyl transferase I, GnT I; TSP, total soluble protein.

### **References**

Aerts JM, Schram AW, Strijland A, van Weely S, Jonsson LM, Tager JM, Sorrell SH, Ginns EI, Barranger JA, Murray GJ. 1988. Glucocerebrosidase, a lysosomal enzyme that does not undergo oligosaccharide phosphorylation. *Biochim. Biophys. Acta.* 964: 303-308.

Aviezer D, Brill-Almon E, Shaaltiel Y, Hashmueli S, Bartfeld D, Mizrachi S, Liberman Y, Freeman A, Zimran A, Galun E. 2009. A plant-derived recombinant human glucocerebrosidase enzyme--a preclinical and phase I investigation. *PLoS ONE* 4, e4792.  
doi:10.1371/journal.pone.0004792.

Berg-Fussman A, Grace ME, Ioannou Y, Grabowski GA. 1993. Human acid beta-glucosidase. N-glycosylation site occupancy and the effect of glycosylation on enzymatic activity. *J. Biol. Chem.* 268: 14861-14866.

Bergmann JE, Grabowski GA. 1989. Posttranslational processing of human lysosomal acid beta-glucosidase: a continuum of defects in Gaucher disease type 1 and type 2 fibroblasts. *Am. J. Hum. Genet.* 44: 741-750.

Beutler E. 1988. Gaucher disease. *Blood Rev.* 2: 59-70.

Bijsterbosch MK, Donker W, van de Bilt H, van Weely S, van Berkel TJ, Aerts JM. 1996. Quantitative analysis of the targeting of mannose-terminal glucocerebrosidase. Predominant uptake by liver endothelial cells. *Eur. J. Biochem.* 237: 344-349.

Beutler E, Grabowski GA. 2001. Gaucher disease. In: Scriver CR et al. editors. *The metabolic and molecular bases of inherited disease*, 8th ed. Vol III. New York: McGraw-Hill. p. 3635-3668.

Boisson M, Gomord V, Audran C, Berger N, Dubreucq B, Granier F, Lerouge P, Faye L, Caboche M, Lepiniec L. 2001. *Arabidopsis glucosidase I* mutants reveal a critical role of N-glycan trimming in seed development. *EMBO J.* 20: 1010-1019.

Boothe J, Nykiforuk C, Shen Y, Zaplachinski S, Szarka S, Kuhlman P, Murray E, Morck D, Moloney MM. 2010. Seed-based expression system for plant molecular farming. *Plant Biotechnol. J.* 8: 588-606.

Brumshtein B, Salinas P, Peterson B, Chan V, Silman I, Sussman JL, Savickas PJ, Robinson GS, Futerman AH. 2010. Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages. *Glycobiol.* 20: 24-32.

Clough SJ, Bent AF. 1998. Floral dip: a simplified method for *Agrobacterium*-mediated transformation of *Arabidopsis thaliana*. *Plant J.* 16: 735-743.

Choy FYM. 1989. Purification of lysosomal membrane-bound glucocerebrosidase from human cultured fibroblasts using high-performance liquid chromatography. *Anal. Biochem.* 179: 312-318.

Dale GL, Beutler E. 1976. Enzyme replacement therapy in Gaucher's disease: a rapid, high-yield method for purification of glucocerebrosidase. *Proc. Natl. Acad. Sci. USA* 73: 4672-4674.

Datla RSS, Hammerlindl JK, Panchuk B, Pelcher LE, Keller W. 1991. A bifunctional fusion between  $\beta$ -glucuronidase and neomycin phosphotransferase: a broad-spectrum marker enzyme for plants. *Gene* 122: 383-384.

De Jaeger G, Scheffer S, Jacobs A, Zambre M, Zobell O, Goossens A, Depicker A, Angenon G. 2002. Boosting heterologous protein production in transgenic dicotyledonous seeds using *Phaseolus vulgaris* regulatory sequences. *Nat. Biotechnol.* 20: 1265-1268.

Downing WL, Galpin JD, Clemens S, Lauzon SM, Samuels AL, Pidkowich MS, Clarke LA, Kermode AR. 2006. Synthesis of enzymatically active human  $\alpha$ -L-iduronidase in *Arabidopsis cgl* (complex glycan-deficient) seeds. *Plant Biotechnol. J.* 4: 169-181.

Downing WL, Hu X, Kermode AR. 2007. Post-transcriptional factors are important for high-level expression of the human  $\alpha$ -L-iduronidase gene in *Arabidopsis cgl* (complex glycan-deficient) seeds. *Plant Sci.* 172: 327-334.

Frank J, Kaulfürst-Soboll H, Rips S, Koiwa H, von Schaewen A. 2008. Comparative analyses of *Arabidopsis complex glycan 1* mutants and genetic interaction with *staurosporin* and *temperature sensitive3a*. *Plant Physiol.* 148: 1354-1367.

Friedman B, Vaddi K, Preston C, Mahon E, Cataldo JR, McPherson JM. 1999. A comparison of the pharmacological properties of carbohydrate remodeled recombinant and placental-derived beta-glucocerebrosidase: implications for clinical efficacy in treatment of Gaucher disease *Blood* 93: 2807-2816.

Furbish FS, Blair HE, Shiloach J, Pentchev PG, Brady RO. 1977. Enzyme replacement therapy in Gaucher's disease: large-scale purification of glucocerebrosidase suitable for human administration. *Proc. Natl. Acad. Sci. USA* 74: 3560-3563.

Furbish FS, Steer CJ, Krett NL, Barranger JA. 1981. Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. *Biochim. Biophys. Acta.* 673: 425-434.

Gomord V, Fischette A C, Menu-Bouaouiche L, Saint-Jore-Dupas C, Plasson C, Michaud D, Faye L. 2010. Plant-specific glycosylation patterns in the context of therapeutic protein production. *Plant Biotechnol. J.* 8: 564-587.

Gomord V, Faye L. 2004. Posttranslational modification of therapeutic proteins in plants. *Curr. Opin. Plant Biol.* 7: 171-181.

Goossens A, Dillen W, De Clercq J, Van Montagu M, Angenon G. 1999. The *arcelin-5* gene of *Phaseolus vulgaris* directs high seed-specific expression in transgenic *Phaseolus acutifolius* and *Arabidopsis* plants. *Plant Physiol.* 120: 1095-1104.

Grabowski GA. 2008. Phenotype, diagnosis, and treatment of Gaucher's disease. *Lancet* 372: 1263-1271.

Grabowski GA. 1997. Gaucher disease: gene frequencies and genotype/phenotype correlations. *Genet. Test.* 1: 5-12.

Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, Parker C, Schiffmann R, Hill SC, Brady RO. 1995. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. *Ann. Intern. Med.* 122: 33-39.

Grabowski GA, Goldblatt J, Dinur T, Kruse J, Svennerholm L, Gatt S, Desnick RJ. 1985. Genetic heterogeneity in Gaucher disease: physicochemical and immunologic studies of the residual enzyme in cultured fibroblasts from non-neuronopathic and neuronopathic patients. *Am. J. Med. Genet.* 21; 529-549.

Ioffe E, Stanley P. 1994. Mice lacking *N*-acetylglucosaminyltransferase I activity die at mid-gestation, revealing an essential role for complex or hybrid N-linked carbohydrates. *Proc. Natl. Acad. Sci. USA* 91: 728-732.

Jonsson LM, Murray GJ, Sorrell SH, Strijland A, Aerts JF, Ginns EI, Barranger JA, Tager JM, Schram AW. 1987. Biosynthesis and maturation of glucocerebrosidase in Gaucher fibroblasts. *Eur. J. Biochem.* 164: 171-179.

Katavic V, Haugh GW, Reed D, Martin M, Kunst L. 1994. *In planta* transformation of *Arabidopsis thaliana*. *Mol. Gen. Genet.* 245: 363-370.

Kermode AR. 2011. Seed Expression Systems for Molecular Farming. In: Wang A, Ma S, editors. *Molecular farming in plants: recent advances and future prospects* New York: Springer, in press. DOI 10.1007/978-94-007-2217-0\_5.

Kermode AR. 2006. Plants as factories for production of biopharmaceutical and bioindustrial proteins: lessons from cell biology. *Can. J. Bot.* 84: 679-694.

Kermode AR. 1996. Mechanisms of intracellular protein transport and targeting. *Crit. Rev. Plant Sci.* 15: 285-423.

Kermode AR, Zeng Y, Hu X, Lauson S, Abrams SR, He X. 2007. Ectopic expression of a conifer *Abscisic Acid Insensitive3* transcription factor induces high-level synthesis of recombinant human  $\alpha$ -L-iduronidase in transgenic tobacco leaves. *Plant Mol. Biol.* 63: 763-776.

Kolarich D, Altmann F. 2000. *N*-Glycan analysis by matrix-assisted laser desorption/ionization mass spectrometry of electrophoretically separated nonmammalian proteins: application to peanut allergen Ara h 1 and olive pollen allergen Ole e 1. *Anal. Biochem.* 285: 64-75.

Koncz C, Schell J. 1986. The promoter of T<sub>L</sub>-DNA gene 5 controls the tissue-specific expression of chimaeric genes carried by a novel type of *Agrobacterium* binary vector. *Mol. Gen. Genet.* 204: 383-396.

Kornhaber GJ, Tropak MB, Maegawa GH, Tuske SJ, Coales SJ, Mahuran DJ, Hamuro Y. 2008. Isofagomine induced stabilization of glucocerebrosidase. *Chembiochem.* 9: 2643-2649.

Kumar R, Yang J, Larsen RD, Stanley P. 1990. Cloning and expression of *N*-acetylglucosaminyltransferase I, the medial Golgi transferase that initiates complex N-linked carbohydrate formation. *Proc. Natl. Acad. Sci. USA* 87: 9948-9952.

Lauriere M, Lauriere C, Chrispeels MJ, Johnson KD, Sturm A. 1989. Characterization of a xylose-specific antiserum that reacts with the complex asparagine-linked glycans of extracellular and vacuolar glycoproteins. *Plant Physiol.* 90: 1182-1188.

Lau OS, Sun SSM. 2009. Plant seeds as bioreactors for recombinant protein production. *Biotechnol. Adv.* 27: 1015-1022.

Lee LS, Muthukumar G, Czuba B, Shorr RGL. 1994. Purification of proteinaceous material. WO/1994/014837.

Leonard R, Kolarich D, Paschinger K, Altmann F, Wilson IB. 2004. A genetic and structural analysis of the N-glycosylation capabilities of rice and other monocotyledons. *Plant Mol. Biol.* 55: 631-644.

Lerouge P, Cabanes-Macheteau M, Rayon C, Fischette-Lainé AC, Gomord V, Faye L. 1998. N-glycosylation of recombinant pharmaceutical glycoproteins produced in transgenic plants: towards an humanisation of plant N-glycans. *Plant Mol. Biol.* 38: 31-48.

Lieberman RL, Wustman BA, Huertas P, Powe AC, Pine CW, Khanna R, Schlossmacher MG, Ringe D, Petsko GA. 2007. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. *Nat. Chem. Biol.* 3: 101-107.

Loos, A, Droogenbroeck BV, Hillmer, S, Grass, J, Kunert, R, Cao J, Robinson DG, Depicker A, Steinkellner, H. 2011. Production of monoclonal antibodies with a controlled N-glycosylation pattern in seeds of *Arabidopsis thaliana*. *Plant Biotechnol. J.* 9: 179-192.

Neuhaus JM, Sticher L, Meins FJ, Boller T. 1991. A short C-terminal sequence is necessary and sufficient for the targeting of chitinases to the plant vacuole. *Proc. Natl. Acad. Sci. USA* 88: 362-366.

Reczek D, Schwake M, Schröder J, Hughes H, Blanz J, Jin X, Brondyk W, Van Patten S, Edmunds T, Saftig P. 2007. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. *Cell* 131: 770-783.

Reggi S, Marchetti S, Patti T, De Amicis F, Cariatì R, Bembi B, Fogher C. 2005. Recombinant human acid  $\beta$ -glucosidase stored in tobacco seed is stable, active and taken up by human fibroblasts. *Plant Mol. Biol.* 57: 101-113.

Saint-Jore-Dupas C, Faye L, Gomord V. 2007. From planta to pharma with glycosylation in the toolbox. *Trends Biotechnol.* 25: 317-323.

Sambrook J, Fritsch EF, Maniatis T. 1989. *Molecular Cloning: A Laboratory Manual*. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press.

Sawkar AR, Cheng WC, Beutler E, Wong CH, Balch WE, Kelly JW. 2002. Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. *Proc. Natl. Acad. Sci. USA* 99: 15428-15433.

Schmitz J, Poll LW, vom Dahl S. 2007. Therapy of adult Gaucher disease. *Hematol. J.* 92: 148-152.

Shaaltiel Y, Bartfeld Y, Hashmueli S, Baum G, Brill-Almon E, Galili G, Dym O, Boldin-Adamsky SA, Silman I, Sussman JL, Futerman AH, Aviezer D. 2007. Production of

glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. *Plant Biotechnol. J.* 5: 579-590.

Sinclair G, Choy FY. 2002. Synonymous codon usage bias and the expression of human glucocerebrosidase in the methylotrophic yeast. *Protein Expr. Purif.* 26: 96-105.

Sinclair GB, Jevon G, Colobong KE, Randall DR, Choy FYM, Clarke LA. 2007. Generation of a conditional knockout of murine glucocerebrosidase: utility for the study of Gaucher disease. *Mol. Genet. Metab.* 90: 148-156.

Steet RA, Chung S, Wustman BA, Powe AC, Do H, Kornfeld SA. 2006. The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. *Proc. Natl. Acad. Sci. USA* 103: 13813-13818.

Stoger E, Ma JK. 2005. Sowing the seeds of success: pharmaceutical proteins from plants. *Curr. Opin. Biotechnol.* 16: 167-173.

Strasser R, Bondili JS, Schoberer J, Svoboda B, Liebminger E, Glössl J, Altmann F, Steinkellner H, Mach L. 2007. Enzymatic properties and subcellular localization of Arabidopsis beta-N-acetylhexosaminidases. *Plant Physiol.* 145: 5-16.

Strasser R, Stadlmann J, Svoboda B, Altmann F, Glössl J, Mach L. 2005. Molecular basis of *N*-acetylglucosaminyltransferase I deficiency in *Arabidopsis thaliana* plants lacking complex *N*-glycans. *Biochem. J.* 387: 385-391.

Takasaki S, Murray GJ, Furbish FS, Brady RO, Barranger JA, Kobata A. 1984. Structure of the *N*-asparagine-linked oligosaccharide units of human placental  $\beta$ -glucocerebrosidase. *J. Biol. Chem.* 259: 10112-10117.

Tropak MB, Kornhaber GJ, Rigat BA, Maegawa GH, Buttner JD, Blanchard JE, Murphy C, Tuske SJ, Coales SJ, Hamuro Y, Brown ED, Mahuran DJ. 2008. Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry. *Chembiochem.* 9: 2650-2662.

Tse YC, Mo B, Hillmer S, Zhao M, Lo SW, Robinson DG, Jiang L. 2004. Identification of multivesicular bodies as prevacuolar compartments in *Nicotiana tabacum* BY-2 cells. *Plant Cell* 16: 672-693.

Twyman RM, Stoger E, Schillberg S, Christou P, Fischer R. 2003. Molecular farming in plants: Host systems and expression technology. *Trends Biotechnol.* 21: 570-578.

Van Patten SM, Hughes H, Huff MR, Piepenhagen PA, Waire J, Qiu H, Ganesa DR, Kutako JP, Edmunds T. 2007. Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease. *Glycobiol.* 17: 467-478.

van Weely S, Aerts JM, Van Leeuwen MB, Heikoop JC, Donker-Koopman WE, Barranger JA, Tager JM, Schram AW. 1990. Function of oligosaccharide modification in glucocerebrosidase, a membrane-associated lysosomal hydrolase. *Eur. J. Biochem.* 191: 667-677.

von Schaewen A, Sturm A, O'Neill J, Chrispeels MJ. 1993. Isolation of a mutant Arabidopsis plant that lacks *N*-acetyl glucosaminyl transferase I and is unable to synthesize Golgi-mediated complex N-linked glycans. *Plant Physiol.* 102: 1109-1118.

Wilson IBH, Harthill JE, Mullin N, Ashford D, Altmann F. 1998. Core  $\alpha$ 1,3-fucose is a key part of the epitope recognized by antibodies reacting against plant N-linked oligosaccharides and is present in a wide variety of plant extracts. *Glycobiol.* 8: 651-661.

Wilson NL, Schulz BL, Karlsson NG, Packer NH. 2002. Sequential analysis of N- and O-linked glycosylation of 2D-PAGE separated glycoproteins. *J. Proteome Res.* 1: 521-529.

## Legends to Figures

**Figure 1.** Production of GCCase in *Arabidopsis cgl* seeds. **A.** Schematic representation of construct used to produce GCCase in *cgl* seeds. ARC 5' + 5'UTR, ARC3' and ARC SP represent sequences from the *ARC5-I* gene - the promoter and 5'-UTR, the 3' end, and the signal peptide (SP)-encoding sequences, respectively. Mature GCCase refers to the human GBA cDNA minus the signal-peptide-encoding sequences. ABCD indicate parts of the expression construct referred to in the experimental procedures section. **B.** GCCase activity of independent transgenic lines. Activities associated with lines 2-43 represent the average value of duplicate assays on the same extract. Activity associated with line 1 was the average value  $\pm$  S.D. derived from three independent experiments on this transgenic line in which assays were done in duplicate or triplicate. **C.** Western blot analysis of GCCase protein in *cgl* seeds of selected independent transgenic lines. Total soluble protein (100  $\mu$ g) was loaded in each lane. GCCase specific activities associated with the independent lines (units/mg TSP) are noted. UT, untransformed *cgl* seeds (negative control). M, pre-stained protein marker.

**Figure 2.** Immunogold EM localization of GCCase in transgenic *cgl* seeds. **A.** Lower magnification of gold-labelled ultrathin section of transgenic *cgl* seed. **B.** Higher magnification of the inset in A. The arrow indicates a gold particle. CW = cell wall.

**Figure 3.** Purified GCCase from transgenic *cgl* seeds. **A.** Purified GCCase (4  $\mu$ g) fractionated by SDS-PAGE. **B.** Western blot analysis of purified GCCase (200 ng of purified GCCase was loaded).

**Figure 4.** Michaelis-Menten plots for *cgl*-GCCase and imiglucerase. Data are the means of three replicate experiments.

**Figure 5.** N-glycan profile of *cgl*-GCCase. Peaks identified as N-glycan signals are labeled. Signals were detected as singly negatively charged  $[M-H]^-$  unless stated otherwise and were confirmed by MS/MS.

**Figure 6.** Anti-horseradish-peroxidase affinity chromatography to remove GCCase containing N-glycan xylose and/or fucose. Western blot analysis used an antibody specific for plant complex N-glycans (Lauriere et al., 1989). Lane 1, 50 ng purified GCCase; lane 2, 50 ng GCCase after passing through an anti-horseradish-peroxidase affinity column.

**Figure 7.** Comparison of uptake of imiglucerase and *cgl*-GCCase by RAW mouse macrophages. GCCase activity immunoprecipitated by a rabbit polyclonal IgG antibody specific for human GCCase from lysates of treated cells.

**Table I.** Purification of GCCase from transgenic *cgl* seeds.








Purification step	Total activity (units)	Specific activity (units/mg TSP)	Purification fold	Yield
Crude extract	57360	22.3	1	100
Con A-Sepharose chromatography	36882	3345	150	64.3
Butyl FF chromatography	13931	43537	2034	24.3
Bio-Gel P 100	7170	48940	2195	12.5

**Table II.** Comparison of enzymatic properties of imiglucerase and *cgl*-GCCase.

	Imiglucerase	<i>cgl</i> -GCCase
$V_{\max}^a$	$254 \pm 4$	$226 \pm 4$
$K_m^b$	$2.34 \pm 0.1$	$2.4 \pm 0.1$
IFG $IC_{50}^c$	$18 \pm 1$	$19 \pm 1$
$T_m^d$	$48.2 \pm 0.6$	$48.4 \pm 0.3$
$T_{m-IFG}^d$	$64.0 \pm 0.3$	$63.8 \pm 0.8$

<sup>a</sup>nmol MU/ng protein/h<sup>b</sup>mM<sup>c</sup>Determined in the presence of 5 mM substrate 4-MUGP<sup>d</sup>°C


**Table III.** N-glycans of *cgl*-derived GCCase.

	Abbrev.	Proposed Structure	Rel. amount (%)	Hex	HexNAc	Fuc	Xyl
<b>Paucimannose and hybrid type structures</b>	Man3XF		9.2	3	2	1	1
	Man5F		3.1	5	2	1	
	Man3GnXF		2.7	3	2	1	1
<b>Oligomannosidic structures</b>	Man4		17.4	4	2		
	Man5		60.2	5	2		
	Man6		1.8	6	2		
	Man7		1.2	7	2		
	Man8		4.5	8	2		


**Table IV.** Stability of GCCase during storage of mature *cgl* seeds

Storage treatment <sup>a</sup>	Total storage days	Activity <sup>b</sup> and % retention of original activity
Freshly harvested	0	24.5
7 days, RT	7	21.1 (86.1%)
14 days, RT	14	20.7 (84.5%)
25 days, RT	25	16.7 (68.2%)
25 days, RT; 7 days, 4°C	32	18.1 (73.9%)
25 days, RT; 30 days, 4°C	55	22.3 (91.0%)
25 days, RT; 90 days, 4°C	115	18.8 (74.5%)


<sup>a</sup>RT=Room Temperature<sup>b</sup>units/mg TSP




**Fig .1**





**Fig .2**




**Fig .3**

**Fig .4**

**Fig .5**



**Fig .6**

**Fig.7**